This is a $300,000 firm fixed-price definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services (HHS), to Neovaxsyn Inc., a minority-owned, self-certified small disadvantaged business. The contract is for the development of a next-generation immunoprevention platform against HIV-1, with a total small business set-aside.
The contract award is tied to a larger Small Business Innovation Research (SBIR) solicitation from NIAID and the Centers for Disease Control and Prevention (CDC), which seeks proposals from small businesses for innovative research to support the agencies' mission needs. The SBIR solicitation includes various research topics related to infectious diseases, vaccines, and medical countermeasures. Neovaxsyn Inc. has previously conducted federal research and development work on HIV/AIDS vaccines, utilizing nanoparticles and antibody-stabilized epitope presentation strategies.
Generated 9/18/24, 9:04 AM